FDA warning on Veozah: Liver injury risk linked to menopausal drug
HQ Team September 13, 2024: The U.S. Food and Drug Administration (FDA) has issued a safety warning about Veozah (fezolinetant), a medication prescribed.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team September 13, 2024: The U.S. Food and Drug Administration (FDA) has issued a safety warning about Veozah (fezolinetant), a medication prescribed.
Molecules and microorganisms in the human body dramatically rise or fall at an average age of 44 and 60 affecting both the heart.
HQ Team April 4, 2024: Britain’s Competition and Markets Authority (CMA) expressed concerns over Theramex’s planned acquisition of Femoston and Duphaston stating it.
By Aparna S March 26, 2024: With a high literacy rate, the migration rates in India’s southern state of Kerala have always been.
HQ Team March 19, 2024: Bayer AG, a German pharmaceutical major, will seek regulatory approval for its menopausal drug after the final trials.
HQ Team May 14, 2023: Astellas Pharma, a Japanese drugmaker, announced that the FDA has approved its oral drug Veozah for the treatment.